Tag: development

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.

DEERFIELD, Ill., July 03, 2025 (GLOBE NEWSWIRE) -- BAB, Inc. (OTCQB: BABB), announced its financial results for the second quarter ended May 31, 2025.

Singapore, July 03, 2025 (GLOBE NEWSWIRE) -- The UPCX innovative open-source blockchain payment platform has announced a new staking event, offering a total reward pool of up to 10,000 UPC (approximately $38,000). The event will run fromJuly 1, 2025, to July 31, 2025, aiming to reward community supporters while promoting the continued development and long-term goals of the UPCX ecosystem.

 

UPCX leverages highly optimized blockchain technology, focusing on fast transactions, high security, and cross-chain interoperability to provide a seamless and convenient payment experience for users, merchants, and institutions. Its governance token,UPC, has been successfully listed on Japan’s compliant exchange BitTrade, as well as prominent platforms such as MEXC, Bitget, Gate.io, WEEX, and Websea.

How to Participate in the UPCX Staking Event

Event Period: July 1, 2025 – July 31, 2025

Official Staking Platform:https://upcx-staking.io/

Reward Claim Form:https://forms.gle/SYs8TwS8jVThEVcf7

Participation Steps

1. Visit the Official Staking PlatformGo to the UPCX official staking platform and connect your wallet.
2. Select Staking Amount and Lockup PeriodEnter the amount of UPC you wish to stake.   Available lockup periods:30 days,90 days, or180 days. Longer lockup periods offer higher reward coefficients.
3. Complete Authorization and Staking

First, complete the[Approve]authorization.
Then, click[Stake Now]to stake and confirm the transaction.
Gas fees incurred during authorization and staking will be reimbursed in equivalent $UPC to your staking wallet address after the event ends.

4. Submit Reward Claim InformationAfter staking, fill out the official reward claim form with your staking details and wallet address to ensure smooth reward distribution.
5. Await Reward DistributionAfter the event concludes, rewards will be distributed to your staking wallet based on the staked amount and lockup period.

The UPCX team reserves the right to the final interpretation of the event. For any questions, please contact official customer support or join the official community for assistance.

Reward Rules

1. Standard Reward Pool

Stake >10 UPC: Share1,500 UPC

Stake >500 UPC: Share2,500 UPC

Stake >1,000 UPC: Share4,000 UPC

2. Long-Term Lockup Bonus Pool

Stake ≥25 UPC, lock for 90 days: Share400 UPC

Stake ≥25 UPC, lock for 180 days: Share600 UPC

More about UPCX:

UPCX is a blockchain-based open-source payment platform that aims to provide secure, transparent, and compliant financial services to global users. It supports fast payments, smart contracts, cross-asset transactions, user-issued assets (UIA), non-fungible tokens (NFA), and stablecoins. Moreover, it offers a decentralized exchange (DEX), APIs, and SDKs, allows customized payment solutions, and integrates POS applications and hardware wallets for enhanced security, building a one-stop financial ecosystem.

UPCX Whitepaper 1.0
https://upcx.io/zh-CN/whitepaper/

UPCX Linktree
https://link3.to/upcx

TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of $1.12, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.